ONCOGENEX PHARMACEUTICALS, INC. (OGXI) is a publicly traded company in the Unknown sector. Across all available filings, 17 corporate insiders have executed 186 transactions totaling $8.5M, demonstrating a bearish sentiment with -$8.1M in net insider flow. The most recent transaction on Jun 12, 2017 involved a transaction of 1,633 shares valued at $588.
No significant insider buying has been recorded for OGXI in the recent period.
No significant insider selling has been recorded for OGXI in the recent period.
Based on recent SEC filings, insider sentiment for OGXI is bearish with an Insider Alignment Score of 3/100 and a net flow of -$8.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ONCOGENEX PHARMACEUTICALS, INC. (OGXI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 17 insiders are actively trading OGXI stock, having executed 186 transactions in the past 90 days. The most active insider is West Capital Ltd Ventures (Executive), who has made 2 transactions totaling $2.7M.
Get notified when executives and directors at OGXI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 12, 2017 | Jacobs Cindy | Executive | Payment | 1,633 | $0.36 | $588 | |
| Jun 12, 2017 | Jacobs Cindy | Executive | Option Exercise | 5,000 | $N/A | $0 | |
| Jun 12, 2017 | Daniel Cormack Scott | Executive | Option Exercise | 9,375 | $N/A | $0 | |
| Jun 12, 2017 | Daniel Cormack Scott | Executive | Option Exercise | 5,000 | $N/A | $0 | |
| Jun 12, 2017 | Daniel Cormack Scott | Executive | Payment | 4,472 | $0.36 | $1.6K | |
| Jan 10, 2017 | Daniel Cormack Scott | Executive | Option Exercise | 20,312 | $N/A | $0 | |
| Jan 10, 2017 | Daniel Cormack Scott | Executive | Option Exercise | 10,312 | $N/A | $0 | |
| Jan 10, 2017 | Daniel Cormack Scott | Executive | Payment | 9,690 | $0.63 | $6.1K | |
| Jan 10, 2017 | Bencich John | Executive | Payment | 1,021 | $0.63 | $643 | |
| Jan 10, 2017 | Bencich John | Executive | Option Exercise | 3,125 | $N/A | $0 | |
| Jan 10, 2017 | Jacobs Cindy | Executive | Option Exercise | 10,312 | $N/A | $0 | |
| Jan 10, 2017 | Jacobs Cindy | Executive | Payment | 3,369 | $0.63 | $2.1K | |
| Aug 19, 2016 | Bencich John | Executive | Sale | 1,380 | $0.57 | $787 | |
| Aug 19, 2016 | Bencich John | Executive | Option Exercise | 5,000 | $N/A | $0 | |
| Jun 13, 2016 | Daniel Cormack Scott | Executive | Sale | 4,856 | $1.03 | $5.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 44 | $8.3M | 84.0% |
Exercise(M) | 97 | $1.3M | 13.0% |
Purchase(P) | 17 | $237.2K | 2.4% |
Payment(F) | 14 | $54.1K | 0.5% |
Gift(G) | 12 | $0 | 0.0% |
Award(A) | 2 | $0 | 0.0% |
Insider selling pressure at ONCOGENEX PHARMACEUTICALS, INC. has increased, with 17 insiders executing 186 transactions across all time. Total sales of $8.3M significantly outpace purchases of $237.2K, resulting in a net outflow of $8.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.